Last reviewed 2026-04-20 · How we verify

Tavist (CLEMASTINE)

At a glance

Approved indications

• Allergic conjunctivitis
• Allergic rhinitis
• Anaphylaxis Adjunct
• Dermatographic urticaria
• Itching of skin
• Nasal congestion
• Nasal discharge
• Sneezing
• Urticaria
• Vasomotor rhinitis

Common side effects

• Urticaria
• drug rash
• anaphylactic shock
• photosensitivity
• excessive perspiration
• chills
• dryness of the mouth
• dryness of the nose
• dryness of the throat
• Hypotension
• headache
• palpitations

Key clinical trials

• Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) (PHASE1,PHASE2)
• Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome (PHASE2)
• Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy (PHASE1,PHASE2)
• Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy (PHASE1,PHASE2)
• Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER) (PHASE2)
• Clemastine Treatment in Individuals With Williams Syndrome (PHASE2)
• A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound (PHASE1,PHASE2)
• CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.